# Addition of acalabrutinib to MBS item 73343 for 17p deletion testing by fluorescent in situ hybridisation (FISH) in patients with relapsed or refractory chronic lymphoid leukaemia (CLL) or small lymphocytic lymphoma (SLL).

* From 1 September 2020, Medicare Benefits Schedule (MBS) item 73343 for 17p deletion testing by fluorescent in situ hybridisation (FISH) testing in patients with relapsed or refractory chronic lymphoid leukaemia (CLL) or small lymphocytic lymphoma (SLL), is changing to to enable testing to determine eligibility for acalabrutinib.
* This change to MBS item 73343 will co-incide with changes to the Pharmaceutical Benefits Scheme (PBS) to make acalabrutinib available to the same eligible patient population (commencing 1 September 2020).
* There will be no change to the schedule fees for MBS item 73343.

## What are the changes?

MBS item 73343 is being amended so that a service can be claimed for 17p deletion testing by FISH in patients with relapsed or refractory CLL or SLL to determine eligibility for PBS listed acalabrutinib. Item 73343 already provides for testing to determine access to the PBS listed drugs idelalisib, ibrutinib and venetoclax.

## Why are the changes being made?

## The Pharmaceutical Benefits Advisory Committee (PBAC) recommended PBS listing of aclabrutinib for this patient population (this is commencing from 1 September 2020).The Medical Services Advisory Committee (MSAC) subsequently supported an application to amend MBS item 73343 to extend 17p deletion testing by FISH to help determine patients eligibility for PBS-subsidised acalabrutinib. MSAC previously advised that 17p deletion testing is safe, clinically effective and cost-effective in patients with SLL and CLL. The Australian Government has approved these changes.

## What does this mean for providers/referrers/other stakeholders?

The addition of acalabrutinib to MBS item 73343 will provide an MBS funded service to assist providers in determining the eligibility of their patient for an additional PBS listed treatment, acalabrutinib.

## How will these changes affect patients?

## 17p deletion testing is a genetic test that checks if people are missing part of their genetic material in their chromosome 17. It is a common genetic change in several types of cancer. The test for 17p deletion is already listed on the MBS to help determine access to idelalisib, ibrutinib and venetoclax, which can help people who have CLL or SLL and who also have a 17p deletion. Acalabrutinib is the most recent medicine to be proposed for listing on the PBS to help this same group of patients. An existing MBS item (73343) will be amended to fund 17p deletion testing for patients who may then be eligible for acalabrutinib as a treatment option.

## Who was consulted on the changes?

Consultation has been undertaken with key stakeholders, clinical experts and providers, and consumer health representatives as part of the MSAC and PBAC processes.

## How will the changes be monitored and reviewed?

Pathology services items will be subject to MBS compliance processes and activities, including random and targeted audits which may require a provider to submit evidence about the services claimed.

Significant variation from forecasted expenditure may warrant review and amendment of fees, and incorrect use of MBS items can result in penalties including the health professional being asked to repay monies that have been incorrectly received.

MBS pathology items will be reviewed by MSAC approximately 24 months post-implementation.

## Where can I find more information?

The full item descriptor(s) and information on other changes to the MBS can be found on the MBS Online website at [www.mbsonline.gov.au](http://www.mbsonline.gov.au). You can also subscribe to future MBS updates by visiting [MBS Online](http://www.mbsonline.gov.au/) and clicking ‘Subscribe’.

The Department of Health provides an email advice service for providers seeking advice on interpretation of the MBS items and rules and the Health Insurance Act and associated regulations. If you have a query relating exclusively to interpretation of the Schedule, you should email [askMBS@health.gov.au](mailto:askMBS@health.gov.au).

Subscribe to ‘[News for Health Professionals](https://www.servicesaustralia.gov.au/organisations/health-professionals/news/all) on the Services Australia website and you will receive regular news highlights.

If you are seeking advice in relation to Medicare billing, claiming, payments, or obtaining a provider number, please go to the Health Professionals page on the Services Australia website or contact Services Australia on the Provider Enquiry Line – 13 21 50.

The data file for software vendors is expected to become available on [date] and can be accessed via the MBS Online website under the Downloads page.

Please note that the information provided is a general guide only. It is ultimately the responsibility of treating practitioners to use their professional judgment to determine the most clinically appropriate services to provide, and then to ensure that any services billed to Medicare fully meet the eligibility requirements outlined in the legislation. This sheet is current as of the Last updated date shown above, and does not account for MBS changes since that date.